NCT03899844

Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

Blood Amyloid-Beta Relationship With Amyloid Plaques and CSF Amyloid-Beta

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,122 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 60 Years
• Healthy volunteers: —

Summary

The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease. Participants will be asked to complete an initial blood collection and cognitive testing, and a subset of participants will be asked to complete a larger blood collection, amyloid PET imaging, and an MRI.

Detailed description

Alzheimer's disease is the most common cause of dementia and currently has no disease-modifying treatments or simple, accurate diagnostic tests. Amyloid beta builds up in the brain and forms plaques in people with Alzheimer's disease, and the buildup of this protein is found decades before symptoms of dementia begin. A blood test may be able to quickly and inexpensively screen people for Alzheimer's disease clinical trials and eventually diagnose Alzheimer's disease in the clinic.

Conditions

• Alzheimer Disease
• Alzheimer Dementia

Interventions

Type	Name	Description
OTHER	Blood collection, PiB PET/MRI, and cognitive testing	Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.

Timeline

• Start date: 2019-04-09
• Primary completion: 2024-01-29
• Completion: 2024-01-31
• First posted: 2019-04-02
• Last updated: 2024-02-13

Locations

1 site across 1 country: United States